查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1357993

器官移植免疫抑制剂市场：依药物类别、移植类型、配销通路和地区分类

Organ Transplant Immunosuppressant Drugs Market, By Drug Class, By Transplant Type, By Distribution Channel, By geography
出版日期: | 出版商: Coherent Market Insights | 英文 176 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2023年，全球器官移植免疫抑制剂市场规模将达51.7亿美元，预计在预测期内（2023-2030年）年复合成长率为3.1%。

报告范围 报告详情
基准年 2022年 2023年市场规模 51.7亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期年复合成长率 3.10% 2030年市场规模预测 64亿美元
2023 年器官移植用免疫抑制剂的全球市场占有率（按药物类别划分）
器官移植免疫抑制剂药物市场-IMG1

现代医学中最复杂和最困难的领域之一是移植相关的药物治疗。大多数药物给药治疗移植排斥和相关问题。人体对移植器官的免疫反应表现为移植排斥反应，通常会导致移植失败，需要立即从接受者身上摘除器官。给药免疫抑制药物和确定供体和受体相容性的血清分型都有助于减少移植排斥。由于全球器官移植数量的增加，预计全球器官移植免疫抑制剂市场将大幅成长。免疫抑制剂对于预防移植后的移植物排斥至关重要，该市场是由器官移植（特别是肾臟、肝臟、心臟和肺移植）的增加所推动的。药物开发的进步，包括标靶治疗治疗和个体化治疗，正在提高药物疗效，同时最大限度地减少副作用。生物相似药和竞争形势正在创造竞争优势，并有可能降低治疗成本。此外，远端医疗和远端监控技术正在提高患者的依从性。

市场动态

器官移植免疫抑制剂市场受益于慢性病的增加。糖尿病、心臟病和肾臟损伤等慢性疾病导致的器官衰竭往往导致需要移植。随着越来越多的人需要挽救生命的器官移植，对免疫抑制剂以防止移植后器官排斥的需求不断增长。例如，截至2023年1月，美国器官移植网络（UNOS）的资料显示，美国等待器官移植的人数与捐赠者器官的供应量之间存在显着差异。 2022年，美国将进行约39,850例器官移植，其中包括已故捐赠者，与前一年同期比较增加4.6%。包括活体器官移植在内，移植器官总数达4,1,887件。这突显了註册捐赠者的重要作用，近 42,000 人获得了生命的第二次开始。然而，器官捐赠的持续需求持续严重供不应求，比例每 10 分钟就有一人被添加到器官捐赠等候名单中。

随着医疗保健系统努力满足这些患者的需求，可能会促进市场扩张。此外，药物开发的改进正在提高这些治疗方法的有效性，并支持市场扩张，以满足器官移植免疫抑制剂日益增长的需求。

本研究的主要特点

  • 本报告对全球器官移植免疫抑制剂市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模和复合年度（年复合成长率）。
  • 它还阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 本文根据公司亮点、产品系列、关键绩效、财务实绩和策略等参数，介绍了全球器官移植免疫抑制剂市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出资讯的决策。
  • 用于器官移植的免疫抑制剂的全球市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于分析全球器官移植免疫抑制剂市场的各种策略矩阵来促进他们的决策。

目录

第1章调查目的和假设

  • 这项研究的目的
  • 假设
  • 简称

第2章市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要

第3章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 最近的趋势
  • 合併、收购和合作
  • 法规场景
  • 主要进展
  • PEST分析
  • 波特的分析

第4章全球器官移植免疫抑制剂市场－新型冠状病毒感染疾病（COVID-19）影响分析

  • 经济影响
  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 对需求和供给的影响

第5章全球器官移植免疫抑制剂市场：依药物类别，2018-2030

  • 钙调磷酸酶抑制剂
  • 抗增殖剂
  • mTOR抑制剂
  • 类固醇
  • 抗体

第6章全球器官移植免疫抑制剂市场：依移植类型分类，2018-2030

  • 肾
  • 肝
  • 心
  • 肺
  • 胰臟
  • 其他的

第7章全球器官移植免疫抑制剂市场：依配销通路，2018-2030

  • 医院药房
  • 零售药房
  • 网路药房

第8章全球器官移植免疫抑制剂市场：依地区划分，2018-2030

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章竞争形势

  • 公司简介
    • Astellas Pharma
    • Genzyme Corporation
    • Accord Healthcare Ltd.
    • Watson Pharmaceuticals, Inc.
    • Novartis AG
    • Mylan Laboratories, Inc.
    • GlaxoSmithKline plc.
    • Belcher Pharmaceuticals LLC
    • Leo Pharma As
    • Glenmark Pharmaceuticals Ltd.
    • TFF Pharmaceuticals, Inc.
    • TolerogenixX GmbH
    • Veloxis Pharmaceuticals Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Panacea Biotec Ltd.
    • Strides Pharma Global Pte Ltd.
    • F.Hoffman La Roche
  • 分析师观点

第10章章

  • 参考
  • 调查方法
简介目录
Product Code: CMI2495

Global organ transplant immunosuppressant drugs market is estimated to be valued at US$ 5.17 billion in 2023 and is expected to exhibit a CAGR of 3.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 5.17 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.10% 2030 Value Projection: US$ 6.4 Bn
Global Organ Transplant Immunosuppressant Drugs Market Share (%), By Drug Class, 2023
Organ Transplant Immunosuppressant Drugs Market - IMG1

One of the most complex and difficult fields in modern medicine is transplant-related medication. The majority of medications are administered to treat transplant rejection and related issues. An immunological reaction by the body to the transplanted organ occurs in transplant rejection, which frequently results in transplant failure and necessitates the removal of the organ from the recipient right away. Immunosuppressive medications and serotyping for determining donor-recipient compatibility can both help to reduce transplant rejection. The global organ transplant immunosuppressant drugs market is poised for substantial growth due to rising organ transplantation procedures worldwide. Immunosuppressant drugs are vital in preventing graft rejection post-transplantation, and the market is driven by the increasing number of organ transplantations, especially kidney, liver, heart, and lung transplants. Advancements in drug development, including targeted and personalized therapies, are enhancing drug efficacy while minimizing adverse effects. Biosimilars and combination therapies are creating competitive landscapes, potentially reducing costs of treatment. Additionally, telemedicine and remote monitoring technologies are improving patient compliance.

Market Dynamics

The market for organ transplant immunosuppressant drugs is benefiting from the rise in the prevalence of chronic diseases. Organ failure from chronic diseases like diabetes, heart disease, and renal disorders frequently results in the need for transplantation. There is a rising need for immunosuppressant medications to prevent organ rejection after transplantation as more individuals need life-saving organ transplants. For instance, as of January 2023, data from the United Network for Organ Sharing (UNOS) revealed that there existed a notable disparity between the number of individuals awaiting organ transplantation and the availability of donor organs in the U.S. Specifically, the national transplant waiting list consisted of over 107,000 individuals seeking organ transplants. In 2022, the U.S. conducted approximately 39,850 organ transplant procedures involving deceased donors, marking a notable 4.6% increase compared to the previous year. The total count of organs transplanted, inclusive of those from living donors, reached 41,887. This underscores the critical role of registered donors, as nearly 42,000 individuals were afforded a second lease on life. However, the persistent demand for organ donations remains substantially higher than the available supply, with an individual being added to the organ waitlist approximately every 10 minutes.

As healthcare systems work to accommodate these patients' requirements, the tendency promotes market expansion. Additionally, improvements in drug development are improving the efficacy of these therapies, helping the market's expansion to meet the increased need for immunosuppressant drugs for organ transplants.

Key features of the study:

  • This report provides an in-depth analysis of the global organ transplant immunosuppressant drugs market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • The study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global organ transplant immunosuppressant drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of the study include Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche
  • Insights from the report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global organ transplant immunosuppressant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global organ transplant immunosuppressant drugs market

Detailed Segmentation:

  • Global Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
    • Calcineurin Inhibitors
    • Antiproliferative Agents
    • mTOR Inhibitor
    • Steroids
    • Antibodies
  • Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
    • Kidney
    • Liver
    • Heart
    • Lung
    • Pancreas
    • Others
  • Global Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Organ Transplant Immunosuppressant Drugs Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Astellas Pharma
    • Genzyme Corporation
    • Accord Healthcare Ltd.
    • Watson Pharmaceuticals, Inc.
    • Novartis AG
    • Mylan Laboratories, Inc.
    • GlaxoSmithKline plc.
    • Belcher Pharmaceuticals LLC
    • Leo Pharma As
    • Glenmark Pharmaceuticals Ltd.
    • TFF Pharmaceuticals, Inc.
    • TolerogenixX GmbH
    • Veloxis Pharmaceuticals Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Panacea Biotec Ltd.
    • Strides Pharma Global Pte Ltd.
    • F. Hoffman La Roche

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Transplant Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Recent Trends
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • PORTER's Analysis

4. Global Organ Transplant Immunosuppressant Drugs Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Organ Transplant Immunosuppressant Drugs Market, By Drug Class, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Calcineurin Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Antiproliferative Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • mTOR Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Steroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Kidney
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Liver
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Heart
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Lung
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Pancreas
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Organ Transplant Immunosuppressant Drugs Market, By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • North America
    • Market Size and Forecast, Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Transplant Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Transplant Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Transplant Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Transplant Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Market Size and Forecast, Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Transplant Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Transplant Type, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Astellas Pharma
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Genzyme Corporation
    • Accord Healthcare Ltd.
    • Watson Pharmaceuticals, Inc.
    • Novartis AG
    • Mylan Laboratories, Inc.
    • GlaxoSmithKline plc.
    • Belcher Pharmaceuticals LLC
    • Leo Pharma As
    • Glenmark Pharmaceuticals Ltd.
    • TFF Pharmaceuticals, Inc.
    • TolerogenixX GmbH
    • Veloxis Pharmaceuticals Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Panacea Biotec Ltd.
    • Strides Pharma Global Pte Ltd.
    • F.Hoffman La Roche
  • Analysts' Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact